The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention

Trial Profile

The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 Status changed from recruiting to discontinued due to low enrollment the sponsor withdrew support for study
    • 19 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top